Mifepristone
Korlym, Mifeprex (mifepristone) is a small molecule pharmaceutical. Mifepristone was first approved as Mifeprex on 2000-09-28. It is used to treat brain neoplasms, ectopic pregnancy, hyperglycemia, and meningeal neoplasms in the USA. The pharmaceutical is active against progesterone receptor and glucocorticoid receptor. In addition, it is known to target nuclear receptor subfamily 1 group I member 2 and androgen receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| nervous system diseases | D009422 |
| urogenital diseases | D000091642 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Korlym, Mifeprex (generic drugs available since 2019-04-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| brain neoplasms | EFO_0003833 | D001932 | C71 |
| ectopic pregnancy | — | D011271 | O00 |
| hyperglycemia | HP_0003074 | D006943 | R73.9 |
| meningeal neoplasms | EFO_0003851 | D008577 | C70 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Mifepristone, Korlym, Corcept Therap | |||
| 10231983 | 2038-08-22 | U-1643 | |
| 10314850 | 2038-08-22 | U-1643 | |
| 10780097 | 2038-08-22 | U-1643 | |
| 10195214 | 2037-06-19 | U-1643 | |
| 10842800 | 2037-06-19 | U-1643 | |
| 10151763 | 2037-01-18 | U-1643 | |
| 9829495 | 2036-08-15 | U-1643 | |
| 10006924 | 2036-08-12 | U-1643 | |
| 10495650 | 2036-08-12 | U-1643 | |
| 9943526 | 2036-04-20 | U-1643 | |
| 10166242 | 2036-04-20 | U-1643 | |
| 10166243 | 2036-04-20 | U-1643 | |
| 10660904 | 2036-04-20 | U-1643 | |
| 10500216 | 2033-03-05 | U-1643 | |
| 10842801 | 2032-11-15 | U-1643 | |
| 8921348 | 2028-08-27 | U-1643 | |
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03X: Other sex hormones and modulators of the genital system in atc
— G03XB: Progesterone receptor modulators, sex hormones and modulators of the genital system
— G03XB01: Mifepristone
— G03XB51: Mifepristone, combinations
HCPCS
Code | Description |
|---|---|
| S0190 | Mifepristone, oral, 200 mg |
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acromegaly | D000172 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | — | 2 | 2 | — | 1 | 3 |
| Growth disorders | D006130 | — | 1 | 3 | — | — | 3 | ||
| Burns | D002056 | T30.0 | — | 1 | 1 | — | — | 1 | |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 3 |
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | — | 1 | — | — | 2 | 3 |
| Myotonic dystrophy | D009223 | G71.11 | 1 | 2 | — | — | — | 2 | |
| X-linked combined immunodeficiency diseases | D053632 | EFO_1001451 | 1 | 1 | — | — | — | 1 | |
| Autism spectrum disorder | D000067877 | F84.0 | — | 1 | — | — | — | 1 | |
| 22q11 deletion syndrome | D058165 | Orphanet_567 | D82.1 | — | 1 | — | — | — | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 1 | — | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | 1 | — | — | — | 1 |
| Duchenne muscular dystrophy | D020388 | 1 | 1 | — | — | — | 1 | ||
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioma | D005910 | EFO_0000520 | 2 | — | — | — | — | 2 | |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | 1 | — | — | — | — | 1 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | 1 | — | — | — | — | 1 | |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Igg deficiency | D017099 | D80.3 | — | — | — | — | 2 | 2 | |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | — | 1 | 1 |
| Osteoporotic fractures | D058866 | — | — | — | — | 1 | 1 | ||
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | — | 1 | 1 | |
| Autoimmune thyroiditis | D013967 | EFO_0006812 | E06.3 | — | — | — | — | 1 | 1 |
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | — | — | — | 1 | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | — | 1 | 1 | |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Ehlers-danlos syndrome | D004535 | Orphanet_98249 | Q79.6 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MIFEPRISTONE |
| INN | mifepristone |
| Description | Mifepristone is a 3-oxo-Delta(4) steroid, an acetylenic compound and a tertiary amino compound. It has a role as an abortifacient, a contraceptive drug, a synthetic oral contraceptive and a hormone antagonist. It derives from a hydride of an estrane. |
| Classification | Small molecule |
| Drug class | steriodal compounds acting on progesterone receptors (excluding-gest- compounds); progesterone receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C |
Identifiers
| PDB | 2W8Y |
| CAS-ID | 84371-65-3 |
| RxCUI | 6964 |
| ChEMBL ID | CHEMBL1276308 |
| ChEBI ID | 50692 |
| PubChem CID | 55245 |
| DrugBank | DB00834 |
| UNII ID | 320T6RNW1F (ChemIDplus, GSRS) |
Target
Alternate
NR1I2
NR1I2
AR
AR
Organism
Homo sapiens
Gene name
NR1I2
Gene synonyms
PXR
NCBI Gene ID
Protein name
nuclear receptor subfamily 1 group I member 2
Protein synonyms
Orphan nuclear receptor PAR1, Orphan nuclear receptor PXR, Pregnane X receptor, Steroid and xenobiotic receptor, SXR
Uniprot ID
Mouse ortholog
Nr1i2 (18171)
nuclear receptor subfamily 1 group I member 2 (O54915)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,807 documents
View more details
Safety
Black-box Warning
Black-box warning for: Korlym, Mpm pak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,598 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more